​​Clinical Trial of Zero Self-Payment Heavy Ion Therapy for Breast Cancer Now Fully Launched​

As the first hospital in China to clinically apply a domestic heavy ion system and the only hospital globally operating two heavy ion systems, Gansu Wuwei Cancer Hospital has accumulated five years of clinical experience, treating over 2,000 patients across more than 50 conditions, including lung cancer, pancreatic cancer, and liver cancer. Clinical efficacy and patient survival rates have reached internationally advanced levels. The hospital has achieved "eight world and domestic firsts": the only hospital globally operating two heavy ion therapy systems; the hospital with the highest number of single-fraction treatments completed within one day; the first globally to develop precision heavy ion therapy under ventilator control; the first globally to implement bladder cancer treatment with precise bladder volume management; the first globally to perform single-session heavy ion therapy using surgically placed spacers between organs and tumors; the first in China to develop a 360° rotatable and adjustable ion therapy chair; the first globally to complete multiple cases of cardiac tumor treatment with heavy ions; and the first globally to integrate heavy ion therapy with comprehensive, lifelong physical and mental health management.

To further advance the high-quality development of heavy ion therapy in China, the hospital will deepen clinical research and drive technological upgrades based on prior achievements. The ​​"Clinical Study on Radical Carbon Ion Radiotherapy for Breast Cancer"​​ has now been launched, aiming to establish China’s clinical standards for heavy ion therapy in breast cancer, aligned with international benchmarks, to pursue better patient outcomes.

Clinical Study on Radical Carbon Ion Radiotherapy for Breast Cancer​

Study Objective

This is a single-center, single-arm, prospective Phase II clinical trial enrolling 42 patients. The study targets breast cancer patients with cT1-3N0-2aM0 staging, using carbon ion radiotherapy for radical treatment to achieve breast-conserving outcomes without surgery. The study aims to evaluate the efficacy and safety of carbon ion therapy for breast cancer.

​​Inclusion Criteria​

1. Age 18–65 years; pathologically confirmed primary breast cancer; clinical stage cT1-3N0-2aM0 (UICC 8th edition);

2. No prior endocrine, targeted, or chemotherapy treatment;

3. No participation in other similar studies;

4. Willingness to sign informed consent and comply with follow-up.

Final eligibility will be determined by investigators based on the trial protocol.

Study Procedures​

1. Screening:​​ After signing informed consent, patients undergo physical examination, imaging (CT/MRI/PET-CT), and laboratory tests.

2. ​​Treatment:​​ Carbon ion radiotherapy with 48 Gy (RBE) to the whole breast and lymphatic drainage area, plus a boost dose of 72–80 Gy (RBE) to the primary tumor, following the latest NCCN guidelines with individualized comprehensive therapy.

3. ​​Follow-up:​​ Regular check-ups at 1, 3, 6, and 12 months post-treatment, then biannually for 10 years.

​​Patient Benefits​

1. The hospital provides research funding to cover heavy ion therapy costs.

2. A multidisciplinary expert team (MDT) will develop a personalized treatment plan.

3. Close follow-up monitoring post-treatment, including provision of subsequent treatment plans.

​​Contact Information

Wuwei Heavy Ion Center, Gansu Wuwei Cancer Hospital​​

   Zhang Yihe: +86 139 9350 8641

​​Lanzhou Heavy Ion Center, Gansu Wuwei Cancer Hospital​

   Qi Ying: +86 139 9350 3180